The GV-backed primary care membership service floated at the bottom of its range but garnered a valution of more than $1.7bn.

Alphabet unit Verily has taken part in an oversubscribed series B round that will fund Mammoth Biosciences' expansion from diagnostics to gene editing and drug development.

Waters Corporation reinvested in the protein characterisation technology producer through an oversubscribed round that will fund innovation and expansion.

Saint Louis University spinout BioIntervene will use the capital to fund phase 1 trials for its non-addictive painkillers later this year.

The university formed 23 new spinouts in 2019, while a total of 33 companies raised a combined $292m – an amount only beaten by 2016’s record-holding $408m.

Wuxi AppTec and Alphabet are in line to exit the molecule-discovery software provider, which has set the range for its initial public offering.

AbbVie Ventures took a board seat through its contribution to the round, closed as the inflammatory disease therapy developer emerged from stealth.

Merck Group spinoff iOnctura will put the $18.7m it raised in the M Ventures-backed round into a clinical trial for its solid tumour therapy.

The inflammatory disease therapy developer emerged from stealth to commercialise research from several Max Planck institutes and LDC.

Scott Brun, who headed AbbVie Ventures until last April, has taken on an R&D advisory role at pharmaceutical company Horizon Therapeutics.